菜单
Telephone sharing button Contact Us linkedin sharing button LinkedIn wechat sharing button YouTube wechat sharing button Twitter mailbox sharing button info@wuxibiologics.com
arrow_left sharing button
arrow_right sharing button

CEO Perspective

Our client relationships expand beyond biotherapeutics as we support companies worldwide in developing vaccines to prevent against existing and future pathogen outbreaks via our subsidiary WuXi Vaccines. In 2023 we expanded further by acquiring a facility dedicated to generating vaccines from both mammalian and microbial expression systems and by building out further our RNA-based vaccine capabilities and expertise. We also helped develop the first hexavalent VLP vaccine.

 

Our commitment to provide our clients around the world a true one-stop discovery to commercialization CRDMO for antibody drug conjugates and other bioconjugates led to over 300 companies entrusting us to bring these novel modalities into the clinic and beyond. We established the subsidiary WuXi XDC to focus specifically on this unique therapeutic class and in order to provide the financial means to support the growth of additional capabilities and most importantly manufacturing capacity of the subsidiary, we achieved a successful Initial Public Offering on the main board of the Hong Kong Stock Exchange and raised approximately $4,071 million Hong Kong dollars. The plans for growth include international expansion into Singapore and providing new technology platforms.

To conclude, it is our client’s endeavors that inspire us to provide the tools, technologies and drug discovery, development and manufacturing services to bring your critical biotherapeutics and vaccines to the clinic and to provide a robust global network of commercial manufacturing across five countries and three continents. Therefore, on behalf of everyone at WuXi Biologics, we would like to extend our sincerest gratitude for your continued partnership and the commitment to make this world a healthier place. And above all, we wish you and your loved ones a wonderful and safe holiday season and a happy new year!

 

Sincerely,

 

Chris Chen

CEO, WuXi Biologics


WuXi Biologics Key CRDMO Milestones